Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patients
Authors:
- 12 May 2023
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 83 (12) , 1158-1166
Abstract
Background: To evaluate the treatment outcomes and toxicity of definitive radiotherapy (RT) for prostate cancer (PC) patients using the simultaneous integrated boost (SIB) technique, which delivered 78 Gy to the entire prostate and 86 Gy to the intraprostatic lesion (IPL) in 39 fractions.Materials and Methods: Univariable and multivariable analyses were conducted of the prognostic factors for freedom from biochemical failure (FFBF), progression‐free survival (PFS), and PC‐specific survival (PCSS) of 619 PC patients who received definitive RT between September 2012 and August 2021. Predictors of late Grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxicities were also identified using logistic regression.Results: The median follow‐up for entire cohort was 68.5 months. The 5‐year FFBF, PFS, and PCSS rates were 93.2%, 83.2%, and 98.6%, respectively. They were predicted by the serum prostate‐specific antigen, Gleason score (GS), clinical nodal stage, and D'Amico risk group. Only 45 patients (7.3%) developed disease recurrence 41.9 months after RT. The 5‐year FFBF rates for low‐, intermediate‐, and high‐risk disease were 98.0%, 93.1%, and 88.5%, respectively (p < 0.001). The 5‐year PFS and PCSS rates according to risk groups were 91.0%, 82.1%, and 77.4% (p < 0.001), and 99.2%, 96.4%, and 95.9% (p = 0.03), and, respectively. GS > 7 and lymph node metastasis negatively predicted FFBF and PCSS in multivariable analysis. Ninety (14.6%) and 44 (7.1%) patients had acute Grade ≥2 GU and GI toxicities, respectively, and 42 (6.8%) and 27 (4.4%) patients had late Grade ≥2 GU and GI toxicities, respectively. Diabetes and transurethral resection independently predicted late Grade 2 GU toxicity, but no significant predictor of late Grade ≥2 GI toxicity was found.Conclusions: Localized PC was effectively and safely treated with definitive RT using the SIB technique to deliver 86 Gy to the IPL in 39 fractions without severe late toxicity. This finding must be validated with long‐term results.Keywords
This publication has 38 references indexed in Scilit:
- Toxicity After External Beam Radiotherapy for Prostate Cancer: An Analysis of Late Morbidity in Men With Diabetes MellitusUrology, 2013
- Does Local Recurrence of Prostate Cancer After Radiation Therapy Occur at the Site of Primary Tumor? Results of a Longitudinal MRI and MRSI StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Intensity-modulated Radiotherapy With Simultaneous Integrated Boost to Dominant Intraprostatic LesionAmerican Journal of Clinical Oncology, 2012
- Late toxicity after conformal and intensity‐modulated radiation therapy for prostate cancer: Impact of previous surgery for benign prostatic hyperplasiaInternational Journal of Urology, 2010
- Dose-escalation using intensity-modulated radiotherapy for prostate cancer – Evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boostRadiotherapy and Oncology, 2009
- Intensity-Modulated Radiotherapy as Primary Therapy for Prostate Cancer: Report on Acute Toxicity After Dose Escalation With Simultaneous Integrated Boost to Intraprostatic LesionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Clinically Significant Prostate Cancer Local Recurrence After Radiation Therapy Occurs at the Site of Primary Tumor: Magnetic Resonance Imaging and Step-Section Pathology EvidenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 GyJournal of Clinical Oncology, 2006
- OUTCOME BASED STAGING FOR CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATEJournal of Urology, 1997